Program 5th Norwegian Myeloma Workshop 2025

Thursday, 22. May

12:00 - 13:00          Lunch

13:00 – 13:10         Opening
// Tobias S. Slørdahl & Fredrik Schjesvold

13:10 – 13:30        The NIMMS study – Study status, preliminary results and plans
// Tobias S. Slørdahl, MD PhD, St. Olavs hospital/NTNU

13:30 – 13:50         A novel CELMOD targeting MYC and Mcl-1 in multiple myeloma
// Mira Tilseth, MD, NTNU/St. Olavs hospital

13:50 – 14:10        The Microbiome project in REMNANT
// Anne-Marie Rasmussen, Oslo Myeloma Center

14:10 – 14:30        Do microbial-derived metabolites play a role in multiple myeloma?
// Pegah Abdollahi PhD, Oslo Myeloma Center

14:30 – 15:00         Break

15:00 – 15:20        Induction of apoptosis in myeloma cells via transcription factor crosstalk
// Toril Holien PhD, NTNU

15:20 – 15:40        Single cell multi-omics to explore how epigenetic and functional states of immune cells shape treatment response to anti-CD38 monoclonal antibodies in multiple myeloma
// Kristin Roseth Aass, PhD, NTNU

15:40 – 16:00         REMNANT – Updated data
// Frida Askeland MD, Oslo Myeloma Center

16:00 – 16:30         Break

16:30 – 16:50         Infection incidence and microbiological pattern in Norwegian myeloma patients
// Juni Songe Paulsen MD, St. Olavs hospital/NTNU

16:50 – 17:10        Assessing safety and renal recovery in newly diagnosed multiple myeloma patients with full dose lenalidomide, a REMNANT study
// Vilhelm Bugge stud.med., Oslo Myeloma Center

17:10 – 17:30        Increased incidence and improved survival in Norwegian myeloma patients from 2000-2023
// Hedda Monsen, stud.med, Oslo Myeloma Center

18:00                      Dinner

Friday, 23. May

08:45 – 08:50         Opening

08:50 – 09:10         Myeloma cells rewire metabolism towards the Warburg effect, but become vulnerable to lactate toxicity
// Magne Børset MD PhD, NTNU/St. Olavs hospital

09:10 – 09:30         Optical single-cell evaluation of drug responses in bone marrow samples
// Kai Sandvold Beckwith PhD, NTNU

09:30 – 09:50         FLUCIPET – A head-to-head comparison of two tracers
// Johan Blakkisrud PhD, OUS

09:50 - 10:10          Break

10:10 - 10:30          Targeting proteostasis in myeloma through inhibition of LTK
// Thea Våtsveen, PhD, OUS

10:30 – 10:50         NOR-ASCT project
// Kari Lenita Falck Moore, Stavanger Universitetssykehus/UiO

10:50 – 11:15         The REST & CONPET
// Frida Askeland MD, and Jakob Nørgaard MD, OUS/UiO

11:15 – 11:30         Break

11:30 – 12:00         Ongoing and upcoming clinical trials in Norway
// NMSG and industry trials – Fredrik Schjesvold, Oslo Myeloma Center  

12:00 – 12:15         Discussions on cooperation and conclusions

12:15                      Lunch and goodbye